Your session is about to expire
← Back to Search
Oncolytic Measles Virus Therapy for Ovarian Cancer
Study Summary
This trial is testing if a measles virus that's been changed to only kill cancer cells can work better than chemotherapy at treating ovarian, fallopian, or peritoneal cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 1 & 2 trial • 48 Patients • NCT00450814Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer can be measured and is outside the belly area.I meet the health and treatment history requirements for safety.My blood, liver, kidney, and heart are functioning within normal ranges.I am eligible for or have chosen DOXIL as part of my treatment plan.You have a disease that can be measured or evaluated based on specific criteria.I am willing to consider surgery for a research port and biopsy if needed.I cannot stop my blood thinner medication for up to 7 days.My cancer did not respond to certain chemotherapy treatments.My ovarian tumor is of a type that tends to grow and spread slowly.I have had both of my ovaries surgically removed.My ovarian, fallopian tube, or peritoneal cancer has returned or worsened after specific treatments.My cancer has spread and formed large tumors.
- Group 1: Arm A (MV-NIS)
- Group 2: Arm B (DOXIL, GEM, TOPA, TAXOL)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there currently any openings for participants in this experiment?
"Affirmative, the information hosted on clinicaltrials.gov confirms that this medical trial is currently recruiting patients. This research was initially posted to the website on March 13th 2015 and has since been revised as of April 8th 2022. Sixty-six participants are needed from three separate sites in order to complete the study's objectives."
Are there any analogous research projects utilizing Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter?
"The Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter was first researched at Spectrum Health Hospital - Butterworth Campus in 1997. 3965 of these studies have been completed and there are currently 1730 trials being conducted largely out of Scottsdale, Arizona."
What medical conditions has Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter been found to alleviate?
"Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter is a frequently used treatment for neoplasm metastasis, in addition to hemorrhage, typhus, and Kaposi's sarcoma AIDS-related."
Is this a pioneering investigation into the subject matter?
"Currently, there are 1730 live trials of the Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter being conducted in 91 countries and 3814 cities. The inception of these studies began with Alfacell's 1997 Phase 3 trial that involved 300 patients. Since then, 3965 investigations have been launched."
How many subjects are involved in this clinical research?
"Affirmative. Clinicaltrials.gov records reveal that recruitment for this medical research commenced on March 13th 2015 and has continued to the present day, with a recent update made on April 8th 2022. 66 individuals are needed from 3 separate locations."
What potential harm could be caused by Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter to individuals?
"Based on the safety data gathered thus far, our team at Power assessed Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter with a score of 2. This is because this Phase 2 trial has only collected evidence that supports its safety and not efficacy."
Share this study with friends
Copy Link
Messenger